Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 944-548-7 | CAS number: -
Endpoint summary
Administrative data
Link to relevant study record(s)
- Endpoint:
- basic toxicokinetics, other
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- data from handbook or collection of data
- Details on absorption:
- Oral absorption:
In the gastrointestinal tract proteins and polypeptides are broken down into a mixture of subunits that are sufficiently small for absorption (i.e. amino acids, di-and tripeptides). Degradation of peptides within the lumen of the gastrointestinal tract may be due to instability in an acidic environment, metabolism by digestive enzymes or luminal microorganisms. Proteolysis starts in the stomach in the presence of pepsin and continues throughout the intestine. Luminal degradation of peptides is caused by exposure to enzymes released from the pancreas into the intestine (Hamman et al. 2005). Insulin is completely inactivated within 3 minutes in gastric fluids from pigs, and in rats less than 1% of insulin was found to be absorbed after oral administration (Smart et al. 2014). The major problem for therapeutic oral insulin administration, besides proteolysis in the stomach and the small intestine, is that there are no selective insulin transport mechanisms across the gut wall and the epithelial cells of the intestinal tract normally do not transport macromolecules. Therefore, even if insulin is dosed directly into the gut, extremely high doses are required to achieve at least some measurable insulin absorption (Heinemann et al 2001).
Thus, due to the structural similarities, the oral absorption of insulin aspart ethyl ester and the read-across source substances may be considered to be minute, which is expected very much to reduce any toxic potential from oral exposure. The low degree of oral absorption may further be supported by the lack of adverse effects noted in acute oral toxicity testing of S2 and S3.
Dermal absorption:
Insulin aspart ethyl ester and the read-across source substances are large proteinaceous molecule and absorption through the skin is expected to be low. Skin is generally considered as a very effective barrier for larger molecules such as polypeptides and proteins. For smaller molecules it has been shown that dermal penetration and absorption has a steep decline when the molecular size of a chemical exceeds 500 Dalton (Bos et al., 2000; Heinemann et al., 2001). Some absorption at a very low percentage of insulin has been observed in hairless mice when applying an electrical potential across the skin (iontophoresis) with the aim of promoting the skin penetration (Heinemann et al. 2001). However, under normal conditions, systemic uptake from dermal exposure to insulin and similar proteins at a molecular size of about 6000 Dalton is considered to be very low / insignificant. The low degree of dermal absorption may further be supported by the lack of adverse effects noted in acute dermal oral toxicity testing of S2.
Inhalational absorption:
Heinemann et al. (2005) reviewed data on the relative biopotency of insulin from the inhalational exposure route (examined as a potential new administration route in insulin therapy) compared to traditional subcutaneous administration. Overall, it was concluded that when using optimal conditions for pulmonary uptake a relative potency of about 10% could achieved from inhalational exposure. Thus, this optimal absorption rate may be considered as a valid assumption in relation to both insulin aspart ethyl ester and the read-across source substances. - Details on excretion:
- T1/2 in plasma of insulin aspart of 22 minutes and 76 minutes have been measured in rats and humans, respectively (Novo Nordisk 1998)
- Details on metabolites:
- No studies regarding identification of metabolites of insulin aspart have been conducted. As for human insulin a fast degradation of insulin aspart into inactive fragments is expected. The amino acids from the substance is expected to take part in the general metabolic pool of the body (Novo Nordisk 1998).
- Conclusions:
- No specific data for Insulin aspart ethyl ester exists.
For human insulin and insulin aspart the oral and demal absorption is considered negligible, because of degradation of the protein in the gastrointestinal tract and due to lack of dermal penetration and absorption of the large, proteinaceous molecule.
From human experiments for the development of inhalation therapy with insulin a relative absorption compared to s.c. injection of 10% has been found.
T1/2 in plasma of insulin aspart of 22 minutes and 76 minutes have been measured in rats and humans, respectively.
No studies regarding identification of metabolites of inuslin aspart have been conducted. As for human insulin, insulin aspart is expected to undergo fast degradation into inactive fragments. The amino acids from the substance is expected to take part in the general metabolic pool of the body. - Executive summary:
No specific data for Insulin aspart ethyl ester exists.
For human insulin and insulin aspart the oral and demal absorption is considered negligible, because of degradation of the protein in the gastrointestinal tract and due to lack of dermal penetration and absorption of the large, proteinaceous molecule.
From human experiments for the development of inhalation therapy with insulin a relative absorption compared to s.c. injection of 10% has been found.
T1/2 in plasma of insulin aspart of 22 minutes and 76 minutes have been measured in rats and humans, respectively.
No studies regarding identification of metabolites of insulin aspart have been conducted. As for human insulin, insulin aspart is expected to undergo fast degradation into inactive fragments. The amino acids from the substance is expected to take part in the general metabolic pool of the body.
- Endpoint:
- basic toxicokinetics, other
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2015
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- test procedure in accordance with national standard methods
- Objective of study:
- other: receptor binding
- GLP compliance:
- no
- Preliminary studies:
- From insulin receptor binding assays (Novo Nordisk 2015) the following relative binding was observed for insulin APIs and the various insulin intermediates:
Human insulin (API, two chains): 100 %
Human insulin methyl ester (two chains): 108 %
DesB 30 human insulin (two chains) : 133 %
X14DesB30 (S3, two chains): not examined
Insulin aspart (API, S1, two chains): 100% %
Insulin aspart ethyl ester (two chains): 103%
Insulin aspart precursor (T, one chain) : 0.03 %
MI3 (S2, one chain): 0.22%
These data indicate that receptor binding affinity is lost when the two amino acids chains are linked together in one chain,
most probably due to a great change in the steric form of the molecule. - Conclusions:
- Human insulin receptor affinity of insulin aspart ethyl ester relative to the API, Insulin aspart, was found to be 103% [92 to 115]. Results are given as weighted means of three independent experiments with the corresponding 95% confidence intervals
- Executive summary:
Human insulin receptor affinity of insulin aspart ethyl ester relative to the API, insulin aspart, was found to be 103% [92 to 115]. Results are given as weighted means of three independent experiments with the corresponding 95% confidence intervals.
Referenceopen allclose all
From insulin receptor binding assays (Novo Nordisk 2015) the following relative binding was observed for insulin APIs and the various insulin intermediates:
Human insulin (API, two chains): 100 %
Human insulin methyl ester (two chains): 108 %
DesB 30 human insulin (two chains) : 133 %
X14DesB30 (S3, two chains): not examined
Insulin aspart (API, S1, two chains): 100 %
Insulin aspart ethyl ester (two chains): 103%
Insulin aspart precursor (T, one chain) : 0.03 %
MI3 (S2, one chain): 0.22%
These data indicate that receptor binding affinity is lost when the two amino acids chains are linked together in one chain,
most probably due to a great change in the steric form of the molecule.
Description of key information
Oral absorption:
In the gastrointestinal tract proteins and polypeptides are broken down into a mixture of subunits that are sufficiently small for absorption (i.e. amino acids, di-and tripeptides). Degradation of peptides within the lumen of the gastrointestinal tract may be due to instability in an acidic environment, metabolism by digestive enzymes or luminal microorganisms. Proteolysis starts in the stomach in the presence of pepsin and continues throughout the intestine. Luminal degradation of peptides is caused by exposure to enzymes released from the pancreas into the intestine (Hamman et al. 2005). Insulin is completely inactivated within 3 minutes in gastric fluids from pigs, and in rats less than 1% of insulin was found to be absorbed after oral administration (Smart et al. 2014). The major problem for therapeutic oral insulin administration, besides proteolysis in the stomach and the small intestine, is that there are no selective insulin transport mechanisms across the gut wall and the epithelial cells of the intestinal tract normally do not transport macromolecules. Therefore, even if insulin is dosed directly into the gut, extremely high doses are required to achieve at least some measurable insulin absorption (Heinemann et al 2001).
Thus, due to the structural similarities, the oral absorption of insulin aspart ethyl ester and the read-across source substances may be considered to be minute, which is expected very much to reduce any toxic potential from oral exposure. The low degree of oral absorption may further be supported by the lack of adverse effects noted in acute oral toxicity testing of S2 and S3.
Dermal absorption:
Insulin aspart ethyl ester and the read-across source substances are large proteinaceous molecule and absorption through the skin is expected to be low. Skin is generally considered as a very effective barrier for larger molecules such as polypeptides and proteins. For smaller molecules it has been shown that dermal penetration and absorption has a steep decline when the molecular size of a chemical exceeds 500 Dalton (Bos et al., 2000; Heinemann et al., 2001). Some absorption at a very low percentage of insulin has been observed in hairless mice when applying an electrical potential across the skin (iontophoresis) with the aim of promoting the skin penetration (Heinemann et al. 2001). However, under normal conditions, systemic uptake from dermal exposure to insulin and similar proteins at a molecular size of about 6000 Dalton is considered to be very low / insignificant. The low degree of dermal absorption may further be supported by the lack of adverse effects noted in acute dermal oral toxicity testing of S2.
Inhalational absorption:
Heinemann et al. (2005) reviewed data on the relative biopotency of insulin from the inhalational exposure route (examined as a potential new administration route in insulin therapy) compared to traditional subcutaneous administration. Overall, it was concluded that when using optimal conditions for pulmonary uptake a relative potency of about 10% could achieved from inhalational exposure. Thus, this optimal absorption rate may be considered as a valid assumption in relation to both insulin aspart ethyl ester and the read-across source substances.
Insulin receptor binding:
Insulin aspart ethyl ester has a realtive binding compared to human insulin of 103% to the human insulin receptor, thus the substance can be expected to have the same biologic mode of action and effects as human insulin.
Key value for chemical safety assessment
- Absorption rate - oral (%):
- 0
- Absorption rate - dermal (%):
- 0
- Absorption rate - inhalation (%):
- 10
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
